Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Internal Medicine

Twice-yearly lenacapavir nearly doubles one-year persistence on HIV PrEP compared with daily pills

Nurse delivering vaccine shot to woman in a clinic setting. Medical and healthcare concept.

Key facts

  • PURPOSE 5 compared twice-yearly injectable lenacapavir with daily oral F/TDF PrEP in the UK and France over 52 weeks.
  • 85.6% of people on lenacapavir stayed persistent on PrEP, compared with 46.3% on daily tablets.
  • There were no HIV acquisitions in the lenacapavir group and one in the daily-tablet group.

What happened

New results from the PURPOSE 5 study, presented at HIV Glasgow 2026, show that people starting HIV pre-exposure prophylaxis (PrEP) with a twice-yearly lenacapavir injection were almost twice as likely to stay on effective prevention for a full year as those starting daily tablets of emtricitabine/tenofovir disoproxil fumarate (F/TDF). Participants in the UK and France who were not already using PrEP were randomly assigned in a 2:1 ratio to the injection or to daily tablets.

After 52 weeks, 85.6% of participants in the lenacapavir group remained persistent, compared with 46.3% in the F/TDF group. Persistence for tablets was confirmed with blood tests showing at least four doses a week. No HIV infections occurred with lenacapavir; one occurred with tablets, in a person whose drug levels showed fewer than two doses a week. Serious adverse events were uncommon in both groups (3.9% and 3.4%) and none were judged related to treatment.

Why it matters

PrEP only works when people keep using it. Missing daily tablets is one of the main reasons prevention fails in real life. A long-acting option given twice a year removes the need to remember a pill every day and may be more discreet. Earlier trials (PURPOSE 1 and 2) had already shown very high protection with lenacapavir; this study adds evidence that people also stay on it far more consistently.

Context

The data come from the manufacturer and from a Phase 2 study, and persistence was measured differently for injections and tablets. Access is another question: an FDA tentative approval of a low-cost generic for lower-income countries was announced earlier this month, but availability and price still vary widely between countries.

What it means for clinicians and students

  • Clinicians: when discussing PrEP, offer the full range of options, including long-acting injections where available, and plan follow-up visits for testing before each dose.
  • Dental and surgical teams: PrEP use is part of a patient’s medication history; ask about it respectfully and keep it confidential.
  • Students: a good example of the difference between efficacy in trials and effectiveness in real life, where adherence drives results.

Source: Gilead Sciences (company release, HIV Glasgow 2026)